CISATRACURIUM BESYLATE

Other

Brand names: Cisatracurium besylate

Intravenous

Mechanism of Action

12.1 Mechanism of Action Cisatracurium besylate injection binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in blockade of neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors such as neostigmine

Indications

See full prescribing information

FDA Warnings

5 WARNINGS AND PRECAUTIONS Residual Paralysis : Patients with neuromuscular diseases are at higher risk
2) Risk of Seizure : Monitor level of neuromuscular blockade during long-term administration to limit exposure to toxic metabolites
4) Risk of Death due to Medication Errors : Accidental administration can cause death
, myasthenia gravis and myasthenic syndrome) and carcinomatosis may be at higher risk of residual paralysis; thus, a lower maximum initial bolus is recommended in these patients [see Dosage and Administration (2

Known Side Effects

3 documented side effects by frequency

Low Blood Pressure

>10%

Drug Not Working

1-10%

Rapid Heart Rate

0.1-1%

Community Discussions

No community discussions found for CISATRACURIUM BESYLATE yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Intravenous